TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04268914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go VR
Description: The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mira Prism VR
Description: The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
Study: NCT00484263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline 6% -
Description: Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
Study: NCT01591629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
Study: NCT00668200

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: 800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
Study: NCT00844649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel (ABI-007)
Description: ABI-007 125 mg/m\^2 administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
Study: NCT01591629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01346124

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Intensity Modulated Proton Radiation
Description: Radiation given once a day Monday-Friday
Study: NCT02935764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 iv gtt, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 400mg/m2 iv, 2400mg/m2 civ 46h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2 iv gtt,d1
Study: NCT03478605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant Pill
Description: Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
Study: NCT03520413

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard VA Home Telehealth
Description: Standard VA HT care coordination and telemonitoring.
Study: NCT03478605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
Study: NCT04735341

Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Ion Endoluminal Procedure for pulmonary nodule
Study: NCT03304964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
Study: NCT04558424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc gluconate and ascorbic acid
Description: This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: zinc gluconate and ascorbic acid
Description: This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
Study: NCT03590080

Intervention type: DRUG
Intervention: Methylprednisolone
Study: NCT01681251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
Description: Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid titrated at the discretion of the attending anesthesiologist
Description: In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
Study: NCT01422616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose rtPA
Description: Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose rtPA
Description: Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure (BP) lowering
Description: Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP management policies
Description: Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
Study: NCT01075217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iopamidol
Description: Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iodixanol
Description: Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
Study: NCT03870607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotics in combination with probiotics
Description: Administration of prebiotics in combination with probiotics before the start of Ch-RT
Study: NCT00869323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 intravenously on Days 1,8, 15 and 22
Study: NCT03304964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
Study: NCT03326830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Description: Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
Study: NCT02660619

Intervention type: OTHER
Intervention: Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)

Intervention type: OTHER
Intervention: Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)
Study: NCT06288958

Intervention type: OTHER
Intervention: Quality of Life and social participation in Italian children with CP
Description: CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
Study: NCT02738996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 60 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 60 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 60 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 60 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 30 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 30 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 30 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 30 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks every 15 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks every 15 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks every 15 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks every 15 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
Study: NCT02365493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Lactam
Study: NCT02985502

Intervention type: OTHER
Intervention: pancreatogenic diabetes
Description: pancreatogenic diabetes
Study: NCT03022669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: American Heart Association patient education website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: American Heart Association patient education website
Study: NCT02982538

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Extended Training in Prolonged Exposure Therapy for PTSD
Description: Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Training in Prolonged Exposure Therapy for PTSD
Description: Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
Study: NCT01277341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Nasal Spray 2% Twice a day
Description: nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Nasal Spray 3% Twice a day
Description: nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Nasal Spray 4% Twice a day
Description: nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: nasal spray
Study: NCT03022669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: American Heart Association patient education website
Study: NCT04429334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: nangibotide 1.0 mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT03060759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Therapy box
Description: The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light Therapy box
Description: The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.
Study: NCT02556307

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
Study: NCT04623021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Administered intravenously as a continuous infusion
Study: NCT04415684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)
Description: For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)
Description: For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
Study: NCT03537157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed release tablets
Description: Active intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator placebo
Study: NCT02358967

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRF (Tocotrienol-rich-fraction)
Description: 2 x 150 mg capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 150 mg capsules
Study: NCT01221246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM602
Description: First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
Study: NCT03883282

Intervention type: OTHER
Intervention: Not Provided
Description: Not Provided

Intervention type: OTHER
Intervention: Not Provided
Description: Not Provided
Study: NCT02396173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Score for non-return to work
Description: The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice).
Study: NCT01978899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Weight Loss Program Group
Description: Participation in 15-week Healthy Living Program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Weight Loss Program Group
Description: Participation in 15-week Healthy Living Program following 15-week wait period.